Celator Pharmaceuticals — Investor Day (July 2014)
138 slides from Celator Pharmaceuticals's investor day presentation, Jul 17, 2014
Slide 1: Celator Pharmaceuticals Analyst Day
a *Celator fos Pharmaceuticals Analyst Day July 17, 2014
Slide 2: Safe Harbor
Safe Harbor To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securit
Slide 3: Agenda
Agenda 9:00 – 9:10 AM: Welcome & Introduction Scott Jackson Chief Executive Officer 9:10 – 9:40 AM: CombiPlex & Why It Is Relevant and Important Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer 9:40 – 10 :0 0 AM: Acute Myeloid Leukemia – Defining Patient Populations and Current St
Slide 4: Agenda
Agenda 10:50 – 11:05 AM: Ongoing and Planned Clinical Studies of CPX - 351 Dr. Arthur Louie Chief Medical Officer 11:05 – 11:25 AM: LLS Commitment to CPX - 351 Dr. Louis J. DeGennaro, Ph.D, Leukemia and Lymphoma Society ® , Interim President and CEO 11:25 – 11 :45 AM: CPX - 351 Commercialization Pla
Slide 5: Welcome & Introduction
Welcome & Introduction Scott Jackson Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 5
Slide 6: Our mission: improve and extend lives of cancer patients
Front Cover Slide Our mission: To improve and extend the lives of patients with cancer
Slide 7: A Pioneer in Development of Cutting Edge Technologies
A Pioneer in Development of Cutting Edge Technologies • Although combination therapy is and will remain the cornerstone of therapy for most cancer patients, traditional strategies to combine drugs fall short of realizing the full potential of combination therapy • CombiPlex ® is a combination - opti
Slide 8: Celator's Proprietary Oncology Pipeline
Celator’s Proprietary Oncology Pipeline 8 CPX - 1 Irinotecan:Floxuridine CPX - 351 Cytarabine:Daunorubicin CPX - 8 (HDPN) Taxane Nanoparticle Research Preclinical Phase 1 Phase 2 Proprietary Technology Platforms Phase 3 Colorectal Cancer Secondary Acute Myeloid Leukemia (Ongoing) Solid Tumors Novel
Slide 9: Building a Broad Pipeline from the CombiPlex Platform
Building a Broad Pipeline from the CombiPlex ® Platform • Why CombiPlex is relevant and important • Understanding CombiPlex and how it works • Plans to advance CombiPlex and widen its application to molecularly targeted therapies • Combinations targeting signaling pathways (i.e. inhibitors of PI3K/A
Slide 10: AML and Opportunity
AML and CPX - 351 Opportunity • Understanding the AML market, in particular secondary AML, and current treatment options • Review of the Phase 1 and 2 studies, with discussion about the key aspects/endpoints of the Phase 3 study • The Leukemia & Lymphoma Society ® and the Therapy Acceleration Progra
Slide 11: Phase 3 Study Design in sAML
CPX - 351 Phase 3 Study Design in sAML 11 Eligibility Confirmation of sAML according to the World Health Organization (WHO) criteria with certain exclusions Age 60 - 75 years Able to tolerate intensive chemo PS 0 - 2 Randomization CPX - 351 7+3 1:1 Randomization Follow - up 150 patients 150 patients
Slide 12: Advantages of the Phase 3 Study
Advantages of the CPX - 351 Phase 3 Study • AML is heterogeneous; single arm studies used to design Phase 3 studies may not be predictive • Two randomized, controlled clinical studies were conducted to identify a patient population, secondary AML, to pursue in Phase 3 • Patient eligibility in the Ph
Slide 13: Upcoming Endpoints in the Phase 3 study
What are the Upcoming Endpoints in the Phase 3 study? 13 Metric Endpoint Phase II (based on Phase 3 eligibility, n=58) Phase III Target (approx.) Timing of Data CR+CRi Secondary 73.7% vs 42.1% 20% 2Q2015 Overall Survival Primary HR=0.40, p=0.004 HR=0.635 1Q2016 • A positive Phase 3 result can be ach
Slide 14: CombiPlex: Why It Is Relevant and Important
CombiPlex ® Why It Is Relevant and Important Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 14
Slide 15: Key Objectives for Technology Update
Key Objectives for Technology Update Why CombiPlex ® is relevant and important Understanding CombiPlex ® and its advantages Advancing CombiPlex ® to widen its application 15
Slide 16: Future of Anti-Cancer Combination Therapies: The Promise
Future of Anti - Cancer Combination Therapies: The Promise 16
Slide 17: Future of Anti-Cancer Combination Therapies: The Problems
Future of Anti - Cancer Combination Therapies: The Problems
Slide 18: Enhancing Efficacy Profile of Drug Combinations
Enhancing Efficacy Profile of Drug Combinations The Solution = CombiPlex ® Control drug ratios after injection • Nano - scale liposomes and nanoparticles engineered to: Stably encapsulate synergistic drug ratios Harmonize PK through controlled release to maintain optimal ratio in vivo Provide
Slide 19: CombiPlex Delivers Sustained, Synergistic Drug Ratios
CombiPlex ® Delivers Sustained, Synergistic Drug Ratios to Increase Anti - tumor Potency Identify drug combinations that exhibit ratio - dependent synergy Fix desired synergistic ratio in effective drug delivery vehicle Deliver and maintain synergistic drug ratio in vivo Increased anti - tumor poten
Slide 20: CombiPlex Delivers the Right Ratio to the Tumor
CombiPlex ® is Critical to Delivering the Right Ratio, to the Tumor, for Prolonged Periods of Time Inject Inject 24 hours CombiPlex ® Maintains Ratio 1 hour Free Drug Cocktail: Ratio changes rapidly 20
Slide 21: Delivery Systems are Key Enablers of CombiPlex
Delivery Systems are Key Enablers of CombiPlex ® Proprietary Liposome and Nanoparticle Platforms Provide Means for Synchronizing Combination PK • Lipid membrane controls drug release rates • Provide differential release control of water soluble and amphipathic drugs • Proprietary active drug loading
Slide 22: Proof of CombiPlex Technology Concept Case Study
Proof of CombiPlex ® Technology Concept CPX - 351 Case Study Proof - of - concept established with approved cytotoxic drug combinations supports application of CombiPlex ® to wide array of drug combinations 22
Slide 23: In Vitro Screening Reveals Ratio-dependent Synergy
CPX - 351 - In Vitro Drug Combination Screening Reveals Ratio - dependent Synergy for Cytarabine:Daunorubicin Cytarabine:Daunorubicin molar ratio of 5:1 maximizes synergy and minimizes antagonism in vitro 1:10 1:5 1:1 5:1 10:1 HCT-116 Colon 0.8 0.7 0.8 0.8 0.8 SW620 Colon 1.0 0.6 0.8 0.7 0.6 Nalm-6
Slide 24: Elevated Exposure to Synergistic Drug Ratios
Hours after injection 0 10 20 30 40 50 Plasma drug concentration ( g/ml) 0.1 1 10 100 1000 Hours after injection 0 5 10 15 20 25 CPX-351 Cyt:Daun Molar Ratio 1 10 Cyt Daun Cyt Daun Key Features Underlying CPX - 351 Efficacy Improvements Provided by CombiPlex ® Elevated exposure to synergistic drug
Slide 25: Prolonged Drug Exposure at Tumor Site
Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine ( g/ml) 0 1 2 3 CPX-351 Free drug cocktail Free Drug CPX - 351 ;allways Prolonged drug exposure at tumor site Key Features Underlying CPX - 351 Efficacy Improvements Provided by CombiPlex ® 25
Slide 26: Selective Delivery to Tumor Cells
Cytarabine Leukemic Cells Normal BM Cells pmol/10 6 cells 0 5 10 15 20 25 30 Daunorubicin Leukemic Cells Normal BM Cells 0 5 10 15 20 25 Liposomes Leukemic Cells Normal BM Cells 0 50 100 150 200 250 Selective delivery to tumor cells pmol Cytarabine/10 6 cells Key Features Underlying CPX - 351 Effica
Slide 27: Dramatic Preclinical Efficacy Improvements
0 20 40 60 80 0 20 40 60 80 100 Dramatic Preclinical Efficacy Improvements WEHI - 3B Monomyelocytic Leukemia Days post cell inoculation % Survival Saline Control CPX - 351 12:5.3 mg/kg Cyt:Daun Free Drugs 300:4.5 mg/kg Cyt:Daun MTD MTD 27
Slide 28: Significant Improvement in Overall Survival in 2 Randomized Studies
Overall Survival 0% 20% 40% 60% 80% 100% 0 3 6 9 12 15 Months from randomization CPX - 351 Median = 6.6 months Salvage Median = 4.2 months CPX - 351 Demonstrated Significant Improvement in Overall Survival in 2 Randomized, Controlled Studies 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomiz
Slide 29: Important Lessons Learned
Important Lessons Learned from CPX - 351 • In vitro informatics on drug ratio - dependent synergy can be translated in vivo using appropriately designed delivery systems • CombiPlex ® results from preclinical models are representative of human experience • PK parameters scaled allometrically from mi
Slide 30: Relevance of CombiPlex for Molecularly Targeted Agent Combinations
Relevance of CombiPlex ® Technology For Molecularly Targeted Agent Combinations 30
Slide 31: Trends in Development of Molecular Targeted Agents
Trends in Development of Molecular Targeted Agents: Important Role of Combinations • Single molecularly targeted agents often have modest or transient antitumor activity • Tumor cell survival is often dictated by multiple targets • Emergence of resistance is more likely to result from targeting one
Slide 32: Rationale for Role of Drug Delivery in Targeted Agent Combinations
Rationale for Role of Drug Delivery in Development of Targeted Agent Combinations • Many combinations will require simultaneous target inhibition • Need for harmonized PK and tumor cell exposure • Conventional dosing formats unable to coordinate exposure due to differential and independent drug dist
Slide 33: CombiPlex Path vs Traditional Path
Go/No Go CombiPlex ® Path Drug A Drug B In Vitro : Identify Synergistic Ratio Formulate at Synergistic Ratio Preclinical PoP at Synergistic Ratio Phase 1 Combo with Synergistic Ratio to MTD Phase 2 Combo with Synergistic Ratio at MTD Months Traditional Path Go/No Go Drug A Drug B In Vitro Preclinica
Slide 34: Parallel Paths to Generate Preclinical CombiPlex Data Packages
Parallel Paths being Pursued to Generate Preclinical CombiPlex ® Data Packages with Targeted Agents Develop independently • Generate data with CombiPlex for 3 targeted combination regimens • In addition, this allows development of single agent nanoparticle pro - drugs for 2 agents Objectives: 1. Est
Slide 35: Targeted Agent Pilot Studies for CombiPlex
Targeted Agent Pilot Studies for CombiPlex ® • Generate data demonstrating feasibility and benefits provided by CombiPlex for combinations of molecularly targeted agents to attract R&D collaborations and/or generate product candidates for internal development • Identify 3 targeted agent combinations
Slide 36: Value-drivers / Benefits of CombiPlex
36 Value - drivers / Benefits of CombiPlex ® Provide the Starting Point for Future Development Priorities CombiPlex® Platform Benefits / Potential Benefits Efficacy: Locking in fixed ratio combinations Efficacy: Greater target selectivity Toxicity: Lower collateral selectivity (e.g., cardio) Potenti
Slide 37: Identifying Opportunities to Leverage CombiPlex Technology
Identify Initial List of ~20 Potential Expansion Opportunities Based on established or potential agent synergy Criteria for Prioritizing Summarize Opportunities, Sequencing 1 2 3 Scientific Clinical Market / Competitive Regulatory Intellectual Property Financial and Other Short - list fo
Slide 38: Combinations Identified for Molecularly Targeted Agents
Combinations Identified for CombiPlex ® Application to Molecularly Targeted Agents Combinations of epigenetic modulators • Histone deacetylase inhibitors; plus • Hypomethylating agents (e.g. azacitidine, Celgene) Combinations targeting major signaling pathways • Inhibitors of PI3K/AKT/mTOR pathway (
Slide 39: Leveraging CombiPlex to Build a Pipeline of Targeted Agents
Leveraging CombiPlex ® to Build a Pipeline of Targeted Agents • In vitro drug ratio dependency can be translated in vivo utilizing drug delivery vehicles, resulting in dramatic improvements in efficacy; preclinical results also translate to clinical improvements • Efficient iterative product generat
Slide 40: AML: Defining Patient Populations and Current Standard of Care
Acute Myeloid Leukemia - Defining Patient Populations and Current Standard of Care Dr. Richard Stone Director, Adult Acute Leukemia Program, Dana Farber Cancer Institute Celator Pharmaceuticals Analyst Day, July 17, 2014 40
Slide 41: AML: Key Points
41 AML: Key Points Richard M. Stone, MD Director, Adult Leukemia Program Dana - Farber Cancer Institute and Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA
Slide 42: AML: What is it and how did it get there?
42 AML: What is it and how did it get there? Unbridled proliferation of hematopoietic stem cells (myeloid lineage) resulting in marrow failure and patient death unless successfully treated Risk factors: AGE, prior chemo for other cancers, ionizing radiation, industrial solvents (last 3 probably
Slide 43: Key Points from de novo AML genome atlas
43 Key Points from de novo AML genome atlas AML genomes have fewer mutations than most other adult cancers (n=13, 5 of which are among the 23 recurrently mutated genes) 9 Key categories: – transcription - factor fusions (18%) – nucleophosmin ( NPM1 ) (27%) – tumor - suppressor genes (16%) – DNA
Slide 44: AML: FAB Classification
44 AML: FAB Classification • M0: Cytochem neg; myeloid Ag on flow • M1: Peroxidase pos. • M2: Perox pos.; some differentiation • M3: Acute Promyelocytic Leukemia • M4: Acute Myelomonocytic Leukemia (perox and NSE pos.) • M5: Acute Monocytic Leukemia (NSE pos) • M6: Acute Erythroleukemia • M7: Acute
Slide 45: WHO Classification of AML
45 WHO Classification of AML • AML with recurrent cytogenetic translocations – t(8;21), t(15;17), 11q23, inv 16 or t(16;16) • AML with multilineage dysplasia – prior MDS • AML, therapy - related – alkylating agent, epipodophyllotoxin - related • 20% blasts, not 30%, constitutes AML, not RAEB - T
Slide 46: Current Risk Assessment in AML
46 Current Risk Assessment in AML Key Prognostic Data in AML in 2013 Patient age Cytogenetics / karyotype Primary versus secondary disease (secondary = post - antecedent hematologic disorder, or therapy - related) Molecular studies: • FLT3 ITD (internal tandem duplication) mutation Unfavorable • NPM
Slide 47: Older Patients With AML Continue to Have Inferior Outcomes
47 Older Patients With AML Continue to Have Inferior Outcomes • Data are based on CALGB & MRC trials for which adults of all ages were eligible Age group Complete remission rate (with “3&7” - like regimens) Early mortality Disease - free survival Long - term overall survival Median survival <60 year
Slide 48: Why Older Patients Experience Inferior Outcomes
48 Why Do Older Patients With AML Experience Inferior Outcomes? • Decreased host tolerance of intensive therapy – Impaired hematopoietic stem cell reserve – Presence of comorbid diseases – Decreased chemotherapy clearance • Increased resistance of disease to therapy – Ratio of favorable (eg, t[8;21]
Slide 49: ELN Guidelines: AML Prognostic Subgroups
49 European Leukemia Net (ELN) Guidelines: AML Genetic - Cytogenetic Prognostic Subgroups Döhner H et al, Blood 2010; 115(3):453 - 474 Genetic Risk Group Survival Subset Favorable 65% • t(8;21)(q22;q22); RUNX1 - RUNX1T1 • inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB - MYH11 • Mutated NPM1 without
Slide 50: Consolidation: DFS Benefit Only in Patients <60 Years
50 100 80 60 40 20 0 ...12…...24…...36…...48…...60…...72….. 84 . ...12…...24…...36…...48…...60…...72….. 84 . Patients in Remission (% ) Age < 60 Age > 60 3 g/m 2 = 156 400 mg/m 2 = 156 100 mg/m 2 = 155 P = 0.0007 3 g/m 2 = 31 400 mg/m 2 = 50 100 mg/m 2 = 48 P = 0.22 Consolidation: DFS Benefit Only i
Slide 51: AML Therapy for Patients <60 Years Old
51 AML Therapy for Patients <60 Years Old Guidelines • Standard induction chemo: “3+7” Daunorubicin 60 - 90 mg/m 2 /d x 3 (or idarubicin 12 mg/m 2 /d x 3) Cytarabine 100 - 200 mg/m 2 /d x 7 continuous infusion • Post - remission (consolidation) therapy: If poor cytogenetics: AlloSCT If favor
Slide 52: Optimal Induction Approach in Older Patients With AML
52 What is the Optimal Induction Approach in Older Patients With AML? • Standard induction : 3&7 (if patient likely to tolerate) – Daunorubicin 45 - 90 mg/m 2 /d x 3d – Cytarabine 100 - 200 mg/m 2 /d x 7d by continuous infusion 1 – Idarubicin or mitoxantrone are not better than daunorubicin 2 – Addi
Slide 53: Selected Lower-Intensity Approaches in Older Patients
53 Selected Lower - Intensity Approaches in Older, Poor Prognosis Patients With AML – Clofarabine 30 mg/m 2 /d x 5d (n = 112) (nucleoside analogue) 1 Median age 71 years, 36% with prior MDS 38% CR, 8% CRp (seen even with several risk factors) Early death rate = 10% – Decitabine 20 mg/m 2 /d x
Slide 54: AML: Where We Are Today
54 AML: Where We Are Today • Under age 55 - 60 years: aggressive induction (3 [dauno 90] +7) and consolidation with high - dose chemo (HDC)/HDC with autologous peripheral blood stem cell transplant (PBSCT) or alloSCT (sibling or matched unrelated donor [MUD]) Post - CR rx moving toward alloSCT in
Slide 55: Secondary AML
55 Secondary AML Definition: AML occurring after prior MDS or after chemo for another cancer New pathophysiology insight - preexisting p53 mutation in HSC clones occur by chance but may be selected for by chemo Prognosis usually poor (basically like that of older adults), but if favorable chromos ca
Slide 56: Secondary AML: Same Mutations as MDS Plus Others
56 Sec AML: Same Mut as MDS Plus Others Walter et al, NEJM 2012
Slide 57: Trial Design
57 Trial Design - 1 • Newly diagnosed patients with secondary AML randomized to: – amonafide 600 mg/m 2 /d IVCI over 4h qd, d 1 - 5, plus ara - C 200 mg/m 2 /d IVCI, d1 - 7 OR – daunorubicin 45 mg/m 2 /d over 30 min d 1 - 3 plus ara - C 200 mg/m 2 /d IVCI, d1 - 7 • If day 14 marrow positive, a 2 nd
Slide 58: Patient Demographics
58 Patient Demographics Amonafide/Ara - C Dauno/Ara - c Age(median) 64.5 63 Race (white) 83% 87% Sex (female) 50% 42% AML w/antecedent MDS 11% 9% WBC>20 18% 19% Elevated LDH 62% 60% Intermediate risk Cytogenetics 34% 33% 433 pts randomized; 23 countries
Slide 59: Primary Endpoint: Complete Remission Rate
59 Primary Endpoint: Complete Remission Rate Amonafide/ara - C (n=216) Daunorubicin/ara - C (n=217) 46% 45% 20.4% 12.4% CR rate 30 d mortality
Slide 60: CR Rate by Cytogenetic Risk
60 CR Rate by Cytogenetic Risk Amonafide/ara - C Daunorubicin ara/C Favorable n=9 100% 88% Int n=146 53% 54% Unfavorable n=173 41% 32% Unknown n=105 43% 46% p=0.001 for overall CR rate by cytogenetic category (Fisher’ s exact test)
Slide 61: Multivariable Analysis for CR Rate
61 Multivariable Analysis for CR Rate P Value Odds ratio Rx arm 0.69 1.084 Elevated LDH 0.01 0.577 Elevated WBC 0.002 0.403 Therapy - related AML 0.02 0.421 Unfavorable Cytogenetic 0.004 0.540
Slide 62: Survival According to Cytogenetic Risk Group
62 Survival According to Cytogenetic Risk Group for Patients With t - AML or De Novo AML Treated by German AML Cooperative Group Karyotype n(%) med OS (mo) t - AML (n = 121) AML (n - 1,511) t - AML AML P Fav 29 (24) 306 (20) 27 NR .02 Inter 34 (28) 903 (60) 12 16 .19 Unfav 58 (48) 302 (20) 6 7 .006
Slide 63: Target-ish Rx in AML - I
63 Target - ish Rx in AML - I • Flavopirodol (combined w chemo) • HSP90 inhibition • NEDD8 inhibition • RAS/MEK inhibition: tipifarib/trametenib • Histone methyltransferase inhib (in MLL re - arranged) • Hedgehog pathway inhibition (combined with chemo) • Proteosome inhibitors (combined with chemo)
Slide 64: Target-ish Rx in AML - II
64 Target - ish Rx in AML - II • New ‘delivery system’: CPX - 351 • Activation of p53: MDM2 inhib • PLK inhibition • HDAC inhibitors (Upfront S1203 trial) • Nuclear export protein inhibitors • MUC - 1 inhibitors • PIM kinase inhibitors • Bromodomain inhibitors • Immune Checkpoint inhibition • TARGET
Slide 65: If Phase 3 Trial is Positive
65 If CPX - 351 Phase 3 Trial is Positive • If the primary OS endpoint is positive : extend survival by several months • It will likely become the standard of care for those who would have been eligible for the phase 3 trial (age 60 - 75) - hopefully increased CR will serve as a ‘better bridge to tr
Slide 66: Acknowledgements
66 Acknowledgements • Clinical Team at DFCI: – Dan DeAngelo, MD, PHD – David Steensma, MD; Martha Wadleigh, MD, Gabi Motyckova, MD, PHD – Ilene Galinsky, NP – Susan Buchanan, PA; Andrian Penicaud, PA, Sarah Cahill, PA, Kat Edmonds, NP • Scientific Team at Dana - Farber/Harvard Cancer Center – Jim Gr
Slide 67: Phase 1 & 2 Clinical Data & the Ongoing Phase 3 Study
CPX - 351 Phase 1 & 2 Clinical Data & the Ongoing Phase 3 Study Dr. Jeffrey Lancet Section Chief of Leukemia, Department of Malignant Hematology, Moffitt Cancer Center Celator Pharmaceuticals Analyst Day, July 17, 2014 67
Slide 68: Timeline of progress in AML
Timeline of “progress” in AML 1950s - 1960s 1970s 1980s 1990s 2000s 2010s Daunorubicin Cytarabine Daunorubicin + Cytarabine Idarubicin + Cytarabine High - dose Cytarabine Gemtuzumab Cladribine Vosaroxin CPX - 351 Sapacitabine Midostaurin HMAs HDAC inhibitors
Slide 69: AML survival in older patients
AML survival: patients ≥ 60 years Burnett et al. Semin Hematol 2006: 43(2):96 - 106 , 0 1 2 3 4 5 6 7 8 0.0 0.2 0.4 0.6 0.8 1.0 Years Survival Probability
Slide 70: Issues delaying development of effective new therapy in AML
Issues delaying the development of effective new therapy in AML • Discovery of molecular anomalies have not yet translated into clear therapeutic targets • Lack of molecular data applied retrospectively to predict response • Trial Design • Empiric testing in a heterogeneous disease • Especially with
Slide 71: CPX-351 liposome composition
CPX - 351 • 100 nm bilamellar liposomes • 5:1 molar ratio of cytarabine to daunorubicin • 1 unit = 1.0 mg cytarabine plus 0.44 mg daunorubicin
Slide 72: Pharmacological Basis of CPX-351
Pharmacological Basis of CPX - 351 CPX - 351 liposome delivers 5:1 molar ratio for >24 hours Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine ( g/ml) 0 1 2 3 CPX-351 Free drug cocktail Cytarabine Accumulates and persists in the bone marrow Preferential uptake and
Slide 73: Phase 1 study of CPX-351 in AML
Phase 1 study of CPX - 351 in AML • First in human study • Relapsed, refractory AML • Dose escalation – planned up to 134 units/m 2 • Primary endpoints – safety, maximum tolerated dose
Slide 74: Phase 1 study: Key Findings
• Safety • Dose limiting toxicity in 3 of 6 patients at 134 units/m 2 • Congestive heart failure, hypertension, prolonged cytopenias • Other most common grade 3 - 4 toxicities • Rash, liver function abnormalities, • Clinical congestive heart failure in 2 of 23 pts (both with heavy prior anthracyclin
Slide 75: Pharmacokinetics
Pharmacokinetics 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 0 24 48 72 96 120 144 168 TIME (hr) Cytarabine Daunorubicin Mean plasma concentration after the day 5 infusion among patients receiving 24 units/m^2 CPX-351 (n=3) D & A detectable 7 days at completion of infusion Fixed molar rati
Slide 76: Randomized Phase 2 Trial vs 7+3 in Older Untreated AML
Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Eligibility • Newly diagnosed • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 (n=84) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 (n=41) Daunorubicin 60 mg/m 2 Cytarabine 100 m
Slide 77: Key demographic features
Key d emographic f eatures CPX - 351 7+3 n=85 n=41 Gender Male 53 (62.4%) 25 (61.0%) Race Caucasian 76 (89.4%) 39 (95.1%) Risk Standard Risk 28 (32.9%) 14 (34.1%) High Risk 57 (67.1%) 27 (65.9%) Age Group ≥70yrs 34 (40.0%) 15 (36.6%) Median (yrs) 68.0 68.0 AML Type De novo AML 52 (61.2%) 22 (53.7%)
Slide 78: Phase 2 Trial Response Results
Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Parameter CPX - 351 (n=84) “7+3” Regimen (n=41) CR (%) 41 (48.8) 20 (48.8) CRi (%) 15 (17.9) 1 (2.4) CR + CRi (%) 56 (66.6) 21 (51.2) 60 - d mortality (%) 4 (4.7) 6 (14.6) CR + CRi (%) in s - AML 19 (57.5) 6 (31.6) s - AML median
Slide 79: Phase 2 Overall Survival
Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML sAML All Patients Overall Survival Overall Survival by treatment arm 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomization Arm A: CPX - 351 Arm B: 7+3 Deaths / N 58 / 85 27 / 41 Median in Mon s . 14.7 ( 10.6 , 18.1 ) 12.
Slide 80: Safety
Safety 80 CPX - 351 (n=85) 7+3 (n=41) n (%) n (%) Grade 3/4 Grade 5 Grade 3/4 Grade 5 Febrile Neutropenia 54 (63.5) 0 (0.0) 21 (51.2) 0 (0.0) Infections 60 (70.6) 3 (3.5) 18 (43.9) 3 (7.3) Bacteraemia 30 (35.3) 0 (0.0) 8 (19.5) 0 (0.0) Epistaxis 6 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) Petechiae 1 (1.2) 0 (0
Slide 81: Outcomes with prior hypomethylating agent exposure
Outcomes in patients with prior hypomethylating agent exposure Prior Hypomethylating Agent Treatment CPX - 351 n=33 (%) 7+3 n=19 (%) +HMA 13 (39%) - HMA 20 (61%) +HMA 7 (37%) - HMA 12 (63%) Responses 7 (54) 12 (60) 2 (29) 4 (33) CR 3 (23) 9 (45) 2 (29) 4 (33) CRi 4 (31) 3 (15) 0 0
Slide 82: Randomized Phase 2 Trial vs Salvage in 1st Relapse AML
Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Eligibility • 1st Relapse • Initial CR ≥1 month • Ages 18 - 65 • Stratified by European Prognostic Index • PS 0 - 2 CPX - 351 (n=81) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations Salvage (as per investigator
Slide 83: Phase 2 Relapse Results
Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Overall (n=125) EPI Poor - Risk ( n=85) CPX - 351 (n=81) Salvage (n=44) CPX - 351 (n=56) Salvage (n=29) Response Rate 49.4% 40.9% 39.3% 27.6% 60 - Day Mortality 14.8% 15.9% 16.1% 24.1% EFS (median, mos.) 4.0 1.4 1.9 1.2 OS (median,
Slide 84: Potential reasons for greater benefit in High-Risk AML
Potential reasons why CPX - 351 has a greater b enefit in High - Risk AML Patients • Altered signaling/cell cycle control checkpoints • 5:1 molar ratio: constant cytarabine excess → daunorubicin DNA damage without blocking cell cycle progression to S - phase where cytarabine action occurs preventing
Slide 85: Randomized Phase 3 Trial vs 7+3 in Older Patients with sAML
Randomized Phase 3 Trial of CPX - 351 vs “7+3” in Older Patients with sAML Eligibility • Previously untreated sAML or tAML • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 Daunorubicin 60 mg/m 2 Cytarab
Slide 86: Phase II study: sAML Definition Phase II vs Phase III
CPX - 351 vs 7+3 Phase II study: sAML Definition Phase II vs. Phase III *Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response Phase III study will use WHO criteria for confirmation of secondary AML 16 patients adde
Slide 87: What makes the AML-301 study unique
What makes AML - 301 unique from other phase 3 AML studies? • Based upon a prior randomized study • Based upon a prior study that identified a distinct group of patients found to benefit from CPX - 351 (secondary AML) • Primary endpoint (overall survival) was modeled upon the primary endpoint from s
Slide 88: Endpoints
Endpoints • Primary • Overall survival with >90% power to detect HR = 0.63 • Detect a 37% decrease in the rate of death with CPX - 351 over the course of the study. • Secondary • Response rate • Event - free survival • 60 day mortality • Leukemia clearance rate
Slide 89: Power calculations
Power calculations Power Hazard Ratio 70 0.726 75 0.712 80 0.697 85 0.679 90 0.657 93.7 0.635 Arm B Rate 31% 42% Power Arm A Rate (%) Difference (%) Arm A Rate (%) Difference (%) 70 46.5 15.5 57.9 15.9 75 47.4 16.4 58.8 16.8 80 48.4 17.4 59.8 17.8 85 49.6 18.6 60.9 18.9 90 51.0 20.0 62.3 20.3 95 53.
Slide 90: Question & Answer Session & Break
Question & Answer Session & Break Celator Pharmaceuticals Analyst Day, July 17, 2014 90
Slide 91: Ongoing and Planned Clinical Studies
Ongoing and Planned Clinical Studies of CPX - 351 Dr. Arthur Louie Chief Medical Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 91
Slide 92: Life Cycle Development
CPX - 351 Life Cycle Development Extend Use to Other AML and Hematologic Malignancies Indications Treatments CPX - 351 alone CPX - 351 + other drugs High - risk AML Other AML indications AML Special Populations Pre - conditioning prior to HSCT CPX - 351 life cycle management is based on high - level
Slide 93: Life Cycle Development Overview
CPX - 351 Life Cycle Development – Overview Completed Ongoing Planned First Line Treatment Older patients – Phase 2 (204 Study) sAML, older patients – Phase 3 High risk, younger patients – Phase 3 AML 19 X X In discussion Second Line and Later Treatment 1 st relapse, younger patients – Phase
Slide 94: Unfit AML Due to Co-morbidities
Unfit AML Due to Co - morbidities: Dr. Walter – Fred Hutchinson Cancer Research Center R CPX-351 32u/m 2 Which dose level, 32 u/m 2 or the 64 u/m 2 or both has acceptable treatment-related mortality (<30%) and improves CR rate (>30%) CPX-351 64u/m 2 Phase II in AML or High-risk MDS: üFirst Line AML,
Slide 95: Unfit AML Due to Poor Risk
Unfit AML Due to Poor Risk: Dr. Cortes - MD Anderson Cancer Center • Newly diagnosed AML at high risk for induction mortality • Unfit AML is estimated to be ~10K patients globally • Typically treated with daunorubicin/cytarabine • Current risk of death is 30 - 50%; objective to lower mortality to <3
Slide 96: Pre-conditioning Prior to HSCT
Pre - conditioning Prior to HSCT: Dr. Gergis - Cornell • AML and High - risk MDS eligible for bone marrow transplant • Unrelated transplants in Adults with AML ~2.7K patients in the U.S. • Objective is <5% blasts before transplant • With current treatments 40% of patients achieve <5% blasts CPX-351
Slide 97: AML and HR-MDS After HMA Therapy
AML and HR - MDS After HMA Therapy: Dr. Medeiros - Stanford • AML or high - risk MDS relapsed or refractory to prior hypomethylating agents • MDS and HMA failure is estimated to be ~5 - 6K patients globally • Median survival in AML is 3.4 months and 5.6 months in MDS, CR rate is 20% • Objective is t
Slide 98: Relapsed/Refractory Hematologic Malignancies (COG Pilot Study)
Relapsed/Refractory Hematologic Malignancies (COG Pilot Study): Dr. Absalon - Cincinnati Children’s Hospital Hypothesis 1. Daunorubicin when administered as CPX - 351 results in less cardiotoxicity compared to standard administration of anthracyclines/anthracenedione 2. Serum biomarkers of cardiotox
Slide 99: Pediatric Leukemia: Pilot Study Rationale
Pediatric Leukemia: Pilot Study Rationale Mulrooney et al. BMJ 2009;339:b4606 99
Slide 100: Life Cycle Development
CPX - 351 Life Cycle Development Extend Use to Other AML and Hematologic Malignancies Indications Treatments CPX - 351 alone CPX - 351 + other drugs High - risk AML Other AML indications AML Special Populations Pre - conditioning prior to HSCT CPX - 351 life cycle management is based on high - level
Slide 101: Leukemia and Lymphoma Society Commitment
Leukemia and Lymphoma Society ® Commitment to CPX - 351 Dr. Louis J. DeGennaro, Ph.D. Leukemia and Lymphoma Society: Interim President and Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 101
Slide 102: What Drives Us
What Drives Us KEY MESSAGE “You have cancer.” “I have an effective treatment for you.” “You are cured.”
Slide 103: Why It's Important
Why It’s Important KEY MESSAGE Anyone can get blood cancer
Slide 104: Cures Today, Not Someday
Cures Today, Not Someday KEY MESSAGE
Slide 105: Confronting a Broad Range of Diseases
0 10 20 30 40 50 60 70 80 90 0% 20% 40% 60% 80% 100% MM NHL CLL CML MPNs HL ALL (Adults) 83,000/ year 2,800/year Incidence Scale AML MDS ALL (Children) Median 5 - year Survival Rate Median Age at Diagnosis Confronting a Broad Range of Diseases with Diverse Outcomes
Slide 106: Why We're Here: The Patients
50% of blood cancer patients survive their diagnosis 50% do not survive Access Cures Why We’re Here: The Patients
Slide 107: LLS Research Has Supported Nearly All Innovative Blood Cancer Treatments
107 Idelalisib (PDUFA review: Sept 11, 2014) Newly approved by FDA in 2013 - 4 LLS Research Has Supported Nearly All Innovative Blood Cancer Treatments
Slide 108: LLS Has Funded Research for 60 Years
Discovery Development Approval New Therapies! Academic Grants Program 108 Therapy Acceleration Program Total funding to date: $1 billion dollars LLS Has Funded Research for 60 Years
Slide 109: Diligence Questions
▪ Unmet medical need - avoiding crowded areas supported by others ▪ Quality of the science and the asset, level of innovation ▪ Competency and enterprise readiness of partner ▪ Value of LLS as a partner More recently: ▪ Strategic fit with LLS research agenda ▪ Potential for a return on investment Di
Slide 110: Celator Partnership
CPX - 351 Celator Partnership
Slide 111: Why Partner with Celator: Unmet Medical Need
0 10 20 30 40 50 60 70 80 90 0% 20% 40% 60% 80% 100% MM NHL CLL CML MPNs HL ALL (Adults) 83,000/ year 2,800/year Incidence Scale AML MDS ALL (Children) Median 5 - year Survival Rate Median Age at Diagnosis Why Partner with Celator: Unmet Medical Need
Slide 112: Compelling Phase 2 Results: Fund the Phase 3 Study
112 Compelling Phase 1 Results: Fund the Phase 2 Study at $4.1 Million
Slide 113: Compelling Phase 2 Results: Fund the Phase 3 Study
Phase 2 study results versus control: ▪ Doubled the number of patients achieving complete remission ▪ Reduced treatment - related mortality by a factor of 5 ▪ Nearly tripled the number of patients alive at one year Compelling Phase 2 Results: Fund the Phase 3 Study at $5 Million
Slide 114: Measures of Success
▪ Direct impact for patients • Changing the standard of care • Demonstrated clinical response throughout the development process • Demonstrated clinical proof of concept ▪ Achieved “expected endpoint” ▪ Partnered Measures of Success
Slide 115: Therapy Acceleration Program Pipeline
INDICATION(S) PRECLINICAL PHASE I PHASE II PHASE III MDS AML MLL Leukemia AML B - Cell Cancers CTCL DLBCL Leukemia Acute Leukemia AML/MDS Myeloma Acute Leukemia Licensed by B - cell Lymphoma Myeloma Acquired by $100 M partnership Licensed by Recent IPO IPO Therapy Acceleration Program Pipeline
Slide 116: Leukemia & Lymphoma Society: A Better Solution for Patients
Academic Research Biotech Pharma FDA Patients & Providers Third - Party Payors Research Grants Venture Philanthropy Policy Advocacy Patient Programs Provider Programs Leukemia & Lymphoma Society A Better Solution for Patients
Slide 117: Commercialization Plans
CPX - 351 Commercialization Plans Derek Miller Chief Business Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 117
Slide 118: Commercial Overview
CPX - 351 Commercial Overview AML Market Place and Opportunity Commercial Plan for CPX - 351 Value of CPX - 351 in AML and beyond 118
Slide 119: Potential Positioning
CPX - 351 Potential Positioning* • For Acute Myeloid Leukemia patients who are deemed appropriate to receive intensive myeloablative therapy, CPX - 351 is the foundational treatment that prolongs survival and reduces treatment - related mortality * For Planning Purposes only and pending FDA approval
Slide 120: AML Market Place and Opportunity
AML Market Place and Opportunity 120
Slide 121: Estimated Proportion of New Leukemia Cases in 2014
Estimated Proportion of New Cases (%) in 2014 for Types of Leukemia, Adults and Children* in the U.S. AML, 18,860 (36%) CLL, 15,720 (30%) ALL, 6,020 (12%) Leukemia, other, 5,800 (11%) CML, 5,980 (11%) Source: Cancer Facts & Figures, 2014 American Cancer Society; 2014. Total is less than 100% due to
Slide 122: Age-specific Incidence Rates for AML
Age - specific Incidence Rates for Acute Myeloid Leukemia in the U.S. (All Races, 2006 - 2010) – Median Age at Diagnosis is 66 122 Source: SEER (Surveillance, Epidemiology and End Results) Cancer Statistics Review, 1975 - 2010. National Cancer Institute; 2013. .
Slide 123: Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market • Bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets • If left untreated, AML progresses rapidly to death • With treatment • Median Overall Survival <12 months for AML patients • Median Overall Survival 6 - 7 months for Se
Slide 124: Treatment Decisions Based on Whether Patient is Fit
In Practice, Treatment Decisions Based on Whether Patient Deemed Suitable for Treatment (i.e. “Fit”) Composite Measure of Age, Performance Status, and Comorbidities Treatment/ Therapy Choice Diagnosis “Fit” “Unfit” Low/Good Risk Cytogenetics Intermediate Risk Cytogenetics High/Poor Risk Cytogenetics
Slide 125: Induction Therapy Used by Region
Induction Therapy Used by Region 100% 100% 100% 100% 20% 20% 6% 11% 18% 27% 29% 13% 47% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% US Europe US Europe US Europe % Frequency of Mentions 7+3 Decitabine Azacitidine LD Ara-C Palliative Care Unfit for intensive Tx Poor/Int Risk Good Risk Source: Results
Slide 126: Commercial Plan
Commercial Plan for CPX - 351 126
Slide 127: Building U.S. Commercialization Plans and Evaluating ex-U.S. Partnering
Building U.S. Commercialization Plans and Infrastructure and Evaluating ex - U.S. Partnering Options U.S. Commercial Prep • KOL and Investigator Engagement • Positioning, Branding, Core Messages • PR • Value Proposition, Access, Reimbursement, and Pricing • Targeting and Segmentation • Staffing in k
Slide 128: Transplant Centers Allow Modest Sales Footprint
48 Centers Performed >70% of AML SCTs Allows Modest Sales Footprint to Cover Concentrated Target Base Department of Health and Human Services, Blood Transplant Report by Center; AML Acute myeloid leukemia - all disease states, number of transplants reported in 2012 website location -- http://bloodce
Slide 129: Centers Participating in Phase 3 Trial
48 Centers Performed >20 more AML SCTs in 2012 23 Participating in CPX - 351 Phase 3 Trial Department of Health and Human Services, Blood Transplant Report by Center; AML Acute myeloid leukemia - all disease states, number of transplants reported in 2012 website location -- http :// bloodcell.transp
Slide 130: Favorable Physician and Payer Reactions to Target Product Profile
Favorable Physician and Payer Reactions to CPX - 351 Target Product Profile • Physicians expressed positive reaction, with an overall rating 5.8 out of 7.0 • “It is a novel new agent with phenomenal complete remission. Recovery of blood count is later, but I don’t mind that. From my point of view th
Slide 131: Value in AML and beyond
Value of CPX - 351 in AML and beyond 131
Slide 132: Projected Revenues in U.S. and Other Markets
Projected Revenues in U.S. and Other Markets Reflect Significant Market Opportunity for CPX - 351 Initial indication of sAML >60 Additional labels and data in AML and other TOTAL United States $120 - 150M ~$290M $410 - 440M ROW $80 - 160M ~$200M $280 - 360M TOTAL $200 - 270M ~490M $690 - 780M Since
Slide 133: Global Market Opportunities Support Life Cycle Plans
Global Market Opportunities are Sufficient to Support Life Cycle Plans Figures are in $millions and represent projected market size
Slide 134: An Attractive Commercial Opportunity
CPX - 351 is an Attractive Commercial Opportunity • Unmet need in AML remains very high • CPX - 351 has the potential to become the standard of care in AML • Treatment patterns in US and key European markets appear to be very similar, allowing for Global Strategy Alignment • Concentrated target audi
Slide 135: Question & Answer Session
Question & Answer Session Celator Pharmaceuticals Analyst Day, July 17, 2014 135
Slide 136: Closing Remarks
Closing Remarks Scott Jackson Chief Executive Officer Celator Pharmaceuticals Analyst Day, July 17, 2014 136
Slide 137: Creating Shareholder Value
Creating Shareholder Value • Execution of the Phase 3 study and preparation for regulatory submission and commercialization • Celator to commercialize CPX - 351 in the US • Seek ex - US partner • Continue to evaluate the potential of CPX - 351 in other patient populations (e.g. AML and other hematol
Slide 138: Expected Milestones and News Flow
138 Expected Milestones and News Flow Estimated dates for data availability from studies Phase 3 Completion of Enrollment Phase 3 Remission Rate Start Technology Platform Programs Phase 3 Overall Survival Complete Technology Platform Programs NDA Submission Technology Platform Programs - TBD 2Q 3Q 4